AstraZeneca withdraws US and EU filings for Zactima in lung cancer
This article was originally published in Scrip
AstraZeneca has withdrawn the US and EU filings of its most advanced anticancer in development, the oral multi-targeted kinase inhibitor Zactima (vandetanib) after regulators failed to be impressed by its efficacy. It had hoped the drug would secure approval as a second-line therapy in non-small cell lung cancer (NSCLC).
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.